The pharmaceutical industry could generate more than $1.2 trillion in global sales in 2025, according to Statista. The cancer segment alone is expected to generate $208 billion in sales this year. The ...

Having asthma, Hashimoto’s thyroiditis or atopic dermatitis in addition to alopecia areata raised the odds for early-onset, severe and prolonged alopecia areata, according to a research letter ...

CVI Pharmaceuticals Ltd. has identified thyroid hormone receptor (THR)-β agonists reported to be useful for the treatment of atherosclerosis, hypercholesterolemia, hyperlipidemia, hepatic steatosis, ...

Today, we're tracking presentations from AbbVie, UCB, WuXi AppTec and several other biopharma firms. Aside from JPM conference coverage, our reporters are making their way around town for one-on ...

Day two of the J.P Morgan Healthcare Conference rolled on with positive data from Sling Therapeutics Inc. that is leading the company to a phase III study in treating thyroid eye disease. The ...

AbbVie has increased its dividend for 52 years ... the rights of which it shares with AstraZeneca, and thyroid eye disease medicine Tepezza, among others. Third, Amgen's pipeline still looks ...

AbbVie is a Dividend King with solid growth ... the rights of which it shares with AstraZeneca, and thyroid eye disease medicine Tepezza, among others. Third, Amgen's pipeline still looks attractive.

Three Motley Fool contributors have identified some especially great high-yield dividend stocks to buy in 2025 -- and all of them are big pharma stocks. Here's why they chose AbbVie(NYSE: ABBV), Amgen ...

They weren’t taking me seriously. After Googling my symptoms, I suspected there might be something wrong with my thyroid - a small, butterfly-shaped gland in the front of the neck that ...

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable ...